Seizing the Value of Class B GPCRs to Develop Novel Drugs for Endocrine & Metabolic Indications
Time: 1:00 pm
day: Pre-Conference Workshop Day
Details:
With the recent successes of GLP-1 drugs such Ozempic and Wegovy, Class B GPCRs are gaining significant interest as they offer new opportunities to address a wide range of unmet patient needs, including endocrine and metabolic indications.
Join this workshop for a deep-dive discussion into the structural and functional understanding of class B GPCRs as well as their physiological and pathophysiological roles to fuel future discovery efforts.
- Exploring dynamic conformational changes of class B GPCRs to better understand their signalling pathways and enabling structure-based drug discovery
- How to expand the existing small molecule and antibody discovery efforts on high-value Class B GPCRs to develop novel drugs for a range of endocrine and metabolic indications including obesity
- How to employ learning from the association between genetic variation of the glucagon-like peptide 1 (GLP-1) receptor gene and obesity to inform future GPCRs targeted drug discoveries in metabolic indications
- Better understanding the structure, the signalling pathways and mechanisms of GPCRs involved in the development of obesity to improve drug discovery efforts
